FDA approves first-in-class drug for polycythemia vera

The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals' Mimrylo (rusfertide) as a new treatment for adults with polycythemia vera who have not achieved adequate control with existing therapies.

How melanoma silences the skin's natural antitumor defense

Cancers actively remodel their surrounding cells and tissues to create a microenvironment that favors their growth, survival and spread. Melanoma, a cancer of the pigment-producing melanocytes of the skin, is one of the most ...

page 13 from 40